Abstract
Lai and colleagues present a nicely written retrospective analysis evaluating the relationship between prescription of abiraterone and enzalutamide to Medicare patients and pharmaceutical manufacturer payments to urologists and medical oncologists. During the years 2014- –2017 promotional payments were made to over one quarter of medical oncologists and one half of urologists who care for Medicare patients. Furthermore, increased payment levels were associated with increased prescription of abiraterone or enzalutamide.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
